Biontech Se-adr (BNTX) 13F Filing Data & Analysis (Q2 2026)

BNTX ranks #2139 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

BNTX is a top-conviction position for GSK plc — at 13.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in BNTX belongs to FMR LLC, but the position matters far more to GSK plc, who has 13.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Quintet Private Bank has added to its BNTX position for two straight quarters, increasing it by $137.8K to reach $188.1K today.

Crocodile Capital Partners GmbH has trimmed its BNTX position for two straight quarters, cutting it by $1.1M while still holding $1.7M.

BNTX is down 2.8% today, and institutions have been net sellers of $21.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

BNTX reported a net loss of $1.1B in its latest fiscal year.

• Not yet profitable — net loss of $1.1B in the latest fiscal year
• Revenue grew 4.3% year over year
• Net income declined year over year, from -$665.3M to -$1.1B
• Generated $456.0M in positive operating cash flow
• Current ratio of 7.54x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.14x equity — within a conventional range